Amarin Pharma Inc. on Tuesday asked the U.S. Supreme Court to decline review of a patent dispute involving generic drug “skinny labels,” arguing that the case centers on fact-specific issues that are ...
Amarin Pharma Inc. on Tuesday asked the U.S. Supreme Court to decline review of a patent dispute involving generic drug “skinny labels,” arguing that the case centers on fact-specific issues that are ...